However, with emerging data demonstrating the cardioprotective effects of newer AHA classes (i.e., GLP-1 receptor agonists and SGLT2 inhibitors), some diabetes management guidelines have been revised to preferentially recommend the initiation of AHAs with demonstrated cardioprotective benefits [8]. Here, SLC5A2 is linked to diabetes mellitus.